Saving changes...

Done

Error

Inflammatory Origins of CRS: Uncovering Opportunities for Disease Prevention and Modification

Inflammatory Origins of CRS: Uncovering Opportunities for Disease Prevention and Modification

Inflammatory Origins of CRS: Uncovering Opportunities for Disease Prevention and Modification

Claus Bachert (MD, PhD), Robert C. Kern (MD), Anju T. Peters (MD), and Martin Wagenmann
Claus Bachert (MD, PhD), Robert C. Kern (MD), Anju T. Peters (MD), and Martin Wagenmann
on behalf of American Academy of Allergy Asthma & Immunology

$15.00 $ 15.00 $ 15.00

$15.00 $ 15.00 $ 15.00

$ 15.00 $ 15.00 $ 15.00
$ 15.00 $ 15.00 $ 15.00
Normal Price: $15.00 $15.00

Review:

Launch date: 28 Jun 2018
Expiry Date:

Last updated: 22 Aug 2018

Reference: 190441

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

The goal of this session is to explore the role of Inflammation in Chronic Rhinosinusitis. As we move away from an infectious etiology as the primary trigger for sinus disease and more toward a complex model if multiple inflammatory pathways, we hope to move this topic toward the practicing clinician.

The mucosal/bacterial interface, whether in a biofilm or as a result of the microbiome is thought to drive much of this inflammation. Additionally, as the role of non-antimicrobial therapy increases for CRS, we will explore some of the new inflammatory pathways and look at the emerging therapies for CRS.

Objectives

Describe the role of the microbiome and biofilms in the development of CRS
Upon completion of this session, participants should be able to describe the role of the microbiome and biofilms in the development of CRS.
Discuss the implications of antibiotic use and overuse in CRS
Upon completion of this session, participants should be able to discuss the implications of antibiotic use and overuse in CRS.
Identify inflammatory pathways in CRS and opportunities for disease modification
Upon completion of this session, participants should be able to identify inflammatory pathways in CRS and opportunities for disease modification.
Claus Bachert (MD, PhD), Robert C. Kern (MD), Anju T. Peters (MD), and Martin Wagenmann

Author Information Play Video Bio

Claus Bachert (MD, PhD), Robert C. Kern (MD), Anju T. Peters (MD), and Martin Wagenmann
on behalf of American Academy of Allergy Asthma & Immunology

Claus Bachert, MD PhD, Universitair Ziekenhuis Gent, Ghent, Belgium

Robert C. Kern, MD, Northwestern University Feinberg School of Medicine, Chicago, IL

Anju T. Peters, MD, Northwestern University Feinberg School of Medicine, Chicago, IL

Martin Wagenmann, MD FAAAAI, Henrich Heine University, Duesseldorf, Germany

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 2.50 Credits
  • California Board of Registered Nursing (CBRN)
  • 2.50 Hours

Faculty and Disclosures

Claus Bachert, MD PhD

Claus Bachert, MD PhD

Potential Conflict

ALK (Ongoing): speaker
Allergopharma: speaker, board
Bionorica (Ongoing): speaker, board
Genentech: board
Meda (Ongoing): speaker, board
MSD (Ongoing): speaker
Novartis (Ongoing): board
Stallergenes (Ongoing): speaker
Uriach (Ongoing): speaker, board
Robert C. Kern, MD

Robert C. Kern, MD

No Conflict
Anju T. Peters, MD

Anju T. Peters, MD

No Conflict
Martin Wagenmann, MD FAAAAI

Martin Wagenmann, MD FAAAAI

Potential Conflict

Heinrich-Heine University Duesseldorf
(Head of Rhinology, Allergy, and
Endoscopic skull base surgery)
Competing Relationships: Speaker –
Allergopharma GmbH & Co KG, Germany,
HAL
Allergies GmbH, Germany, ALK-Abello,
Germany, Meda Pharma, Germany;
Consultant –
Bionorica SE, Germany, HAL Allergies
GmbH, Germany; Advisory Board – Meda
Pharma,
Germany, ALK Abello
Organizational Interests: German Society
of Allergology and Clinical Immunology
(Ongoing):
Head of the Section Otorhinolaryngology

Speaker: Allergopharma GmbH & Co KG,
Germany
Consultant: Bionorica SE, Germany
Speaker: HAL Allergies GmbH, Germany
Consultant: HAL Allergies GmbH, Germany
Advisory Board: Meda Pharma, Germany
Speaker: ALK-Abello, Germany
Speaker: Meda Pharma, Germany
Advisory Board: ALK Abello

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error